Researchers have identified a protein that powers the virulence of the bacteria that causes gonorrhea, opening the possibility of a new target for antibiotics and, even better, a vaccine.
The findings, published today in PLOS Pathogens, are especially important since the microbe, Neisseria gonorrhoeae, is considered a “superbug” because of its resistance to all classes of antibiotics available for treating infections.
Gonorrhea, a sexually transmitted disease that results in 78 million new cases worldwide each year, is highly damaging if untreated or improperly treated.
It can lead to endometritis, pelvic inflammatory disease, ectopic pregnancy, epididymitis and infertility. Babies born to infected mothers are at increased risk of blindness.
“The infections very often are silent,” said Oregon State University researcher Aleksandra Sikora. “Up to 50 percent of infected women don’t have symptoms, but those asymptomatic cases can still lead to some very severe consequences for the patient’s reproductive health, miscarriage or premature delivery.”
The need for better antibiotic therapy, and a vaccine, is pressing. N. gonorrhoeae strains resistant to the last effective treatment options have emerged, and failures in treatment are occurring.
Sikora and her research team at the OSU/OHSU College of Pharmacy and Ann Jerse’s lab at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, collaborated to discover a novel lipoprotein that N. gonorrhoeae uses to defeat the body’s first line of innate immune defense.
The body relies on enzymes known as lysozymes that, as their name suggests, thwart bacteria by causing their cell wall to lyse, or break apart. Lysozymes are abundant both in epithelial cells, which make up the tissue on the outside of organs and the inside of body cavities, and in the phagocytic cells that protect the body by ingesting foreign particles and bacteria.
In turn, many gram-negative bacteria – characterized by their cell envelope that includes a protective outer membrane – have developed ways of defeating lysozymes. Prior to the work by Sikora’s team, however, only one lysozyme-fighting protein had been discovered in the Neisseria genus.
Now that new targets have been identified, they can be explored as bullseye candidates for new antibiotics or a vaccine – if the lysozyme inhibitor can itself be inhibited, then the bacteria’s infection-causing ability is greatly reduced.
Sikora and her collaborators named the new protein SliC, short for surface-exposed lysozyme inhibitor of c-type lysozyme.
Studying SliC’s function in culture as well as in a gonorrhea mouse model – mice were infected with N. gonorrhoeae, then checked for SliC expression at one, three and five days – researchers determined the protein was essential to bacterial colonization because of its anti-lysozyme role.
“This is the first time an animal model has been used to demonstrate a lysozyme inhibitor’s role in gonorrhea infection,” Sikora said. “Together, all of our experiments show how important the lysozyme inhibitor is. This is very exciting.”
Receive an email update when we add a new GONORRHEA article.
The Latest on: Gonorrhea
via Google News
The Latest on: Gonorrhea
Gonorrhea Vaccine to be Developed Soon After Intense Protein Analysis
on November 12, 2018 at 3:34 am
The findings, published in Molecular and Cellular Proteomics, are especially important since the microbe, Neisseria gonorrhoeae, is considered a "superbug" because of its resistance to all classes of ... […]
Gonorrhea is on the rise, with few options to treat it
on November 11, 2018 at 11:00 am
Gonorrhea (Neisseria gonorrhoeae) is a sexually transmitted infection (STI) that has been with us for a long time. There are descriptions of conditions that fit with gonorrhea — penile burning, discha... […]
Low-Salt Diet and Heart Failure; New Gonorrhea Tx: It's PodMed Double T!
on November 10, 2018 at 11:11 am
PodMed Double T is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine, and Rick Lange, MD, president of the Texas Tech University Health ... […]
OSU researchers closer to gonorrhea vaccine
on November 8, 2018 at 4:45 pm
Microscopic image of the bacteria that causes gonorrhea (Photo: Ryszard Zielke, OSU/OHSU College of Pharmacy). Microscopic image of the bacteria that causes gonorrhea (Photo: Ryszard Zielke, OSU/OHSU ... […]
New Antibiotic Helps Against 'Super Gonorrhea'
on November 8, 2018 at 10:52 am
WEDNESDAY, Nov. 7, 2018 (HealthDay News) -- Untreatable, antibiotic-resistant gonorrhea has become a chilling prospect in the United States, raising concerns that people might someday have to live wit... […]
Researchers closer to gonorrhea vaccine after exhaustive analysis of proteins
on November 8, 2018 at 7:03 am
In a study of proteins historic in its scope, researchers at Oregon State University have pushed closer both to a vaccine for gonorrhea and toward understanding why the bacteria that cause the ... […]
New single-dose antibiotic safe and effective for uncomplicated gonorrhea
on November 8, 2018 at 5:17 am
A phase 2 clinical trial led by Stephanie N. Taylor, MD, Professor of Medicine and Microbiology in the Section of Infectious Diseases at LSU Health New Orleans School of Medicine, has found that a new ... […]
Minnesota Man Accused of Raping His Girlfriend's 4-year-old Daughter, Giving Her Gonorrhea
on November 8, 2018 at 4:31 am
A Minnesota man has been charged after his girlfriend’s 4-year-old daughter reportedly tested positive for gonorrhea, a sexually-transmitted infection. KMSP (Fox9) reported the St. Paul man, identifie... […]
Novel antibiotic shows promise in treatment of uncomplicated gonorrhea
on November 7, 2018 at 11:22 pm
Colorized scanning electron micrograph of Neisseria gonorrhoeae bacteria, which causes gonorrhea. Credit: NIAID An investigational oral antibiotic called zoliflodacin was well-tolerated and ... […]
via Bing News